Vertex Pharmaceuticals Files 8-K on Financials
Ticker: VRTX · Form: 8-K · Filed: May 5, 2025 · CIK: 875320
Sentiment: neutral
Topics: financial-reporting, 8-K, sec-filing
Related Tickers: VRTX
TL;DR
VERTEX files 8-K for financial updates, investors watch closely.
AI Summary
Vertex Pharmaceuticals Incorporated filed an 8-K on May 5, 2025, to report on its results of operations and financial condition, as well as to file financial statements and exhibits. The filing pertains to the period ending May 5, 2025.
Why It Matters
This filing provides investors with crucial updates on Vertex Pharmaceuticals' financial performance and condition, impacting investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or unusual risks.
Key Players & Entities
- Vertex Pharmaceuticals Incorporated (company) — Registrant
- Massachusetts (location) — State of incorporation
- 000-19319 (other) — Commission File Number
- 04-3039129 (other) — I.R.S. Employer Identification No.
- 50 Northern Avenue Boston, Massachusetts 02210 (location) — Principal executive offices address
- May 5, 2025 (date) — Date of report
FAQ
What is the primary purpose of this Form 8-K filing for Vertex Pharmaceuticals?
The primary purpose is to report on the company's results of operations and financial condition, and to file financial statements and exhibits.
When was this Form 8-K filed?
This Form 8-K was filed on May 5, 2025.
What is Vertex Pharmaceuticals' state of incorporation?
Vertex Pharmaceuticals is incorporated in Massachusetts.
What is the address of Vertex Pharmaceuticals' principal executive offices?
The address is 50 Northern Avenue, Boston, Massachusetts 02210.
What is the Commission File Number for Vertex Pharmaceuticals?
The Commission File Number is 000-19319.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 5, 2025 regarding VERTEX PHARMACEUTICALS INC / MA (VRTX).